Tagraxofusp

Phase 2

TherapeuticsMD, Inc. (TXMD)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Acute Myeloid Leukemia

SGENLintuzumab (SGN-33)

Phase 2

View Full Landscape

Drug Information

Target Indication

Acute Myeloid Leukemia

Clinical Trial

NCT06456463

Last updated: 7/3/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA1/7/2021

Elzonris

Elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

TXMD

TherapeuticsMD, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

KarXTPhase 3

Psychosis Associated With Alzheimer's Disease

DexycuPhase 3

Inflammation

enclomiphene citratePhase 3

Effect of Treatment on Bone Mineral Density

REL-1017Phase 3

Major Depressive Disorder

ETC-1002Phase 3

Hypercholesterolemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts